Massachusetts General Hospital Cancer Center, Boston, MA.
American Society of Clinical Oncology, Alexandria, VA.
J Clin Oncol. 2020 Jul 20;38(21):2438-2453. doi: 10.1200/JCO.20.00611. Epub 2020 May 20.
To provide evidence-based guidance on the clinical management of cancer cachexia in adult patients with advanced cancer.
A systematic review of the literature collected evidence regarding nutritional, pharmacologic, and other interventions, such as exercise, for cancer cachexia. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and systematic reviews of RCTs published from 1966 through October 17, 2019. ASCO convened an Expert Panel to review the evidence and formulate recommendations.
The review included 20 systematic reviews and 13 additional RCTs. Dietary counseling, with or without oral nutritional supplements, was reported to increase body weight in some trials, but evidence remains limited. Pharmacologic interventions associated with improvements in appetite and/or body weight include progesterone analogs and corticosteroids. The other evaluated interventions either had no benefit or insufficient evidence of benefit to draw conclusions on efficacy. Limitations of the evidence include high drop-out rates, consistent with advanced cancer, as well as variability across studies in outcomes of interest and methods for outcome assessment.
Dietary counseling may be offered with the goals of providing patients and caregivers with advice for the management of cachexia. Enteral feeding tubes and parenteral nutrition should not be used routinely. In the absence of more robust evidence, no specific pharmacological intervention can be recommended as the standard of care; therefore, clinicians may choose not to prescribe medications specifically for the treatment of cancer cachexia. Nonetheless, when it is decided to trial a drug to improve appetite and/or improve weight gain, currently available pharmacologic interventions that may be used include progesterone analogs and short-term (weeks) corticosteroids.
为成人晚期癌症患者癌症恶病质的临床管理提供基于证据的指导。
系统检索了关于营养、药物和其他干预措施(如运动)治疗癌症恶病质的文献,包括随机对照试验(RCT)和 RCT 的系统评价。检索了 PubMed 和 Cochrane Library 从 1966 年 10 月 17 日发表的 RCT 及系统评价。ASCO 召集了一个专家小组来审查证据并制定建议。
综述包括 20 项系统评价和 13 项额外的 RCT。饮食咨询,无论是否口服营养补充剂,在一些试验中被报道能增加体重,但证据仍然有限。与改善食欲和/或体重相关的药物干预包括孕激素类似物和皮质类固醇。其他评估的干预措施要么没有益处,要么证据不足以得出疗效结论。证据的局限性包括高脱落率,与晚期癌症一致,以及研究之间对感兴趣的结局和结局评估方法的差异。
可以提供饮食咨询,目的是为恶病质的管理为患者和护理人员提供建议。不应常规使用肠内喂养管和肠外营养。鉴于缺乏更有力的证据,不能推荐任何特定的药物干预作为标准治疗;因此,临床医生可能不会选择专门开处方药物来治疗癌症恶病质。尽管如此,当决定试用一种药物来改善食欲和/或增加体重时,目前可使用的药物干预包括孕激素类似物和短期(数周)皮质类固醇。